NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from the New York State Department of Health (NYSDOH) for its TERT test offering, which is designed to detect a molecular biomarker of thyroid cancer aggressiveness.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.